PharmaEssentia (TPE:6446) has submitted an application to Brazil's Health Regulatory Agency (ANVISA) to add essential thrombocythemia (ET) as a new indication for its drug BESREMi (ropeginterferon alfa-2b), according to a Wednesday filing to the Taiwan Stock Exchange.
The company's shares were down over 3% in recent trade.
The post-marketing variation application seeks approval for treating adults with ET, a rare blood disorder characterized by excessive platelet production.
ANVISA's review period is 60 days for priority applications and 180 days for ordinary applications, excluding requests for additional information
BESREMi was approved in Brazil in March 2025 for treating adults with polycythemia vera. It is already approved for ET in several markets, including the US, Japan, and China.
Comments